Multiple Sclerosis Performance Test: Technical Development and Usability

ConclusionPatients with MS with varying disability levels completed the MSPT with minimal or no supervision, resulting in comprehensive, efficient, standardized, quantitative, clinically meaningful data collection as part of routine medical care, thus allowing for large-scale, real-world evidence generation.FundingBiogen.Trial RegistrationNCT02664324.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research

Related Links:

Authors: Łabuz-Roszak B, Niewiadomska E, Kubicka-Bączyk K, Skrzypek M, Tyrpień-Golder K, Majewska A, Matejczyk A, Dobrakowski P, Pierzchała K Abstract OBJECTIVES: Pain is one of the most frequently reported symptoms of multiple sclerosis (MS). It affects the daily functioning of patients, limits the ability to work and reduces the joy of life. The aim of the study was to analyze the impact of pain on quality of life as well as symptoms of anxiety and depression in patients with MS. METHODS: The study included 144 patients with diagnosed MS (mean age 41±12 years, mean illness duration 10.3±8.6 ...
Source: Psychiatria Polska - Category: Psychiatry Tags: Psychiatr Pol Source Type: research
AbstractIntroductionFingolimod has demonstrated clinical and MRI benefits versus placebo/interferon β-1a in young adults with multiple sclerosis (MS). Here we report the long-term effects of fingolimod 0.5 mg on clinical and MRI outcomes in young adults with MS aged ≤ 30 years followed up for up to 8 years (96 months).MethodsThis post hoc analysis of pooled FREEDOMS/FREEDOMS II studies included patients who either received fingolimod 0.5  mg from randomization (immediate;N = 163) or switched from placebo to fingolimod at month (M) 24 (delayed;N = 14...
Source: Neurology and Therapy - Category: Neurology Source Type: research
Neuroinflammation is a prominent pathological feature of all neuroimmunological diseases, including, but not limited to, multiple sclerosis (MS), myasthenia gravis, neuromyelitis optica, and Guillain–Barré syndrome. All currently-approved therapies for the treatment of these diseases focus on controlling or modulating the immune (innate and adaptive) responses to limit demyelination and neuronal damage. The primary purpose of this review is to detail the pre-clinical data and proposed mechanism of action of novel drugs currently in clinical trial, with a focus on novel compounds that promote repair and regener...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Multiple sclerosis (MS) is a neurodegenerative disease characterized by lesions in the central nervous system. Inflammation and demyelination are the leading causes of neuronal death and brain lesions formation. The immune reactivity is believed to be essential in the neuronal damage in MS. Cytokines play important role in differentiation of Th cells and recruitment of auto-reactive B and T lymphocytes that leads to neuron demyelination and death. Several cytokines have been found to be linked with MS pathogenesis. In the present study, serum level of eight cytokines (IL-1β, IL-2, IL-4, IL-8, IL-10, IL-13, IFN-γ...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
ABSTRACT Multiple sclerosis (MS) is an autoimmune, inflammatory, and degenerative disease of the central nervous system. Axonal degeneration is triggered by inflammation and is the pathological substrate of progressive disability in patients with MS. Therapeutic interventions can reduce inflammatory activity, thus delaying neurodegeneration and the progression of disability. Disease activity and neurodegeneration are assessed mainly through clinical evaluation and magnetic resonance imaging. These measures lack sensitivity and accuracy, so new biomarkers are necessary. Several markers have been studied and to date the most...
Source: Arquivos de Neuro-Psiquiatria - Category: Neurology Source Type: research
ConclusionsLow levels of openness and extroversion traits are associated with a greater risk of developing time-based PM deficit. Therefore, personality assessment and behavioural interventions should be encouraged in MS clinical practice.
Source: Journal of Neurology - Category: Neurology Source Type: research
Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The disease’s course is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the disease’s course. Over the past two decades, the disease’s treatment landscape has changed tremendously. Currently, more than a dozen drugs representing 10 substances with different mechanisms of action have been approved (interferon beta preparations, glatiramer acetate, fingolimod, siponim...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This study enrolled 23 consecutive patients who were treated with alemtuzumab from 2015 to 2018. Efficacy was evaluated using the annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS), and radiological activity. No evidence of disease activity (NEDA) was defined as no clinical relapse, no worsening of the EDSS score, and no radiological activity. The safety profiles were also assessed. RESULTS: The mean age was 36 years and 16 of the patients were female. Seventeen and 12 of 23 patients were followed up for 1 year and 2 years, respectively. The ARR was markedly reduced from 1.52 during the 1-year perio...
Source: Journal of Clinical Neurology - Category: Neurology Tags: J Clin Neurol Source Type: research
ConclusionsPatients with MS considered relapse rate, disability progression, severe adverse events, route of administration, frequency of administration, and out-of-pocket cost, when they chose DMTs. Their WTPs for DMTs varied widely.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
ConclusionsPLEX is an overall well-tolerated second-line treatment option for pediatric patients with severe acute CNS demyelinating events with limited response to PS.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
More News: Brain | Disability | Drugs & Pharmacology | Multiple Sclerosis | Neurology | Study